Albireo Pharma (ALBO) Prices 4M Share Common Offering at $40/Sh

Albireo Pharma (ALBO) Announces Proposed Public Offering of 3M Shares of Common Stock

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of 3,000,000 shares of its common stock. In connection with the offering, Albireo intends to grant the... More

Albireo Pharma (ALBO) PT Raised to $62 at Wedbush, After Study Results Published

Wedbush analyst Liana Moussatos raised the price target on Albireo Pharma (NASDAQ: ALBO) to $62.00 (from $55.00) while maintaining a Outperform rating.

Albireo Pharma (ALBO) PT Raised to $79 at Jefferies

Jefferies analyst Eun Yang raised the price target on Albireo Pharma (NASDAQ: ALBO) to $79.00 (from $50.00) while maintaining a Buy rating.

Albireo Pharma (ALBO) PT Raised to $68 at Needham & Company

Needham & Company analyst Alan L. Carr raised the price target on Albireo Pharma (NASDAQ: ALBO) to $68.00 (from $50.00) while maintaining a Buy rating.

Albireo Pharma (ALBO) PT Raised to $67 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce raised the price target on Albireo Pharma (NASDAQ: ALBO) to $67.00 (from $50.00) while maintaining a Buy rating.

The analyst commented, "This morning, Albireo announced positive topline results from the global, pivotal, Phase 3 PEDFIC 1 trial (NCT03566238) of lead drug, odevixibat (40 µg/kg/day or 120 µg/kg/day oral dose), for the treatment of children (aged 6 months to 16 years) with progressive familial intrahepatic cholestasis (including PFIC1 and non-truncated PFIC2). PEDFIC 1 met the difficult-to-achieve U.S. regulatory (FDA) primary efficacy endpoint of pruritus improvement (as measured by the PRUCISION 0-4 scale instrument)... More

Albireo Pharma (ALBO) PT Raised to $81 at Piper Sandler, After Study Results Published

Piper Sandler analyst Yasmeen Rahimi raised the price target on Albireo Pharma (NASDAQ: ALBO) to $81.00 (from $45.00) while maintaining a Overweight rating.

Albireo Pharma (ALBO) PT Raised to $67 at Baird

Baird analyst Brian Skorney raised the price target on Albireo Pharma (NASDAQ: ALBO) to $67.00 (from $52.00) while maintaining a Outperform rating.

Pre-Open Movers 09/08: (ALBO) (NKLA) (SPRO) Higher; (CRBP) (ACMR) (TSLA) Lower (more...)

Pre-Open Stock Movers:

Albireo Pharma Inc. (NASDAQ: ALBO) 79% HIGHER; announced positive topline results from PEDFIC 1, a global Phase 3 clinical trial evaluating the efficacy and safety of odevixibat and the largest study ever conducted in PFIC1 and PFIC2. PEDFIC 1 met its two primary endpoints, demonstrating that odevixibat reduced serum bile acid responses (sBAs) (p=0.003) and improved pruritus assessments (p=0.004) with a single digit diarrhea rate. Odevixibat is a highly potent, non-systemic ileal bile acid transport inhibitor (IBATi), for the treatment of progressive familial intrahepatic cholestasis (PFIC) patients.

Corbus Pharmaceuticals... More

Albireo Pharma (ALBO) Reports Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC

(Updated - September 8, 2020 6:39 AM EDT)

Albireo Pharma Inc. (NASDAQ: ALBO) today announced positive topline results from PEDFIC 1, a global Phase 3 clinical trial evaluating the efficacy and safety of odevixibat and the largest study ever conducted in PFIC1 and PFIC2. PEDFIC 1 met its two primary endpoints, demonstrating that odevixibat reduced serum bile acid responses (sBAs) (p=0.003) and improved pruritus assessments (p=0.004) with a single digit diarrhea rate. Odevixibat is a highly potent, non-systemic ileal bile acid transport inhibitor (IBATi), for the treatment of progressive familial intrahepatic cholestasis (PFIC) patients.

In the... More